

Table 14-3.07
ADAS Cog (11) - Change from Baseline to Week 24 - Completers at Wk 24-Observed Cases-Windowed

	Placebo (N=60)	Xanomeline Low Dose (N=28)	Xanomeline High Dose (N=30)
Baseline			
n	59	27	30
Mean (SD)	23.2 (11.74)	24.0 (13.89)	20.5 (11.50)
Median (Range)	21.0 (5;51)	20.0 (5;57)	18.0 (3;49)
Week 24			
n	59	27	30
Mean (SD)	25.3 (13.32)	24.1 (11.87)	21.8 (12.60)
Median (Range)	23.0 (5;58)	22.0 (8;51)	18.5 (3;44)
Change from Baseline			
n	59	27	30
Mean (SD)	2.1 (5.89)	0.1 (5.86)	1.3 (4.51)
Median (Range)	2.0 (-11;16)	1.0 (-11;12)	1.0 (-7;13)
p-value(Dose Response) [1][2]			0.234
p-value(Xan - Placebo) [1][3]		0.105	0.461
Diff of LS Means (SE)		-2.1 (1.26)	-0.9 (1.22)
95% CI		(-4.6;0.4)	(-3.3;1.5)
p-value(Xan High - Xan Low) [1][3]			0.430
Diff of LS Means (SE)			1.2 (1.47)
95% CI			(-1.8;4.1)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Note that only assessments falling within the assessment window are included in the summary for a visit.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006